Cooper Financial Group Buys 5,654 Shares of Boston Scientific Corporation $BSX

Key Points

• Cooper Financial Group increased its stake in Boston Scientific by 207.6% during the second quarter, purchasing an additional 5,654 shares to reach a total of 8,377 shares worth approximately $900,000.
• Boston Scientific reported a $0.75 EPS for the last quarter, exceeding analysts' estimates of $0.72, with revenues of $5.06 billion, up 22.8% year-over-year.
• Research analysts have set a positive outlook on Boston Scientific, with target prices raised by several firms, leading to an average price target of $120.67 with a majority rating as "Buy".

Cooper Financial Group raised its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 207.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,377 shares of the medical equipment provider's stock after purchasing an additional 5,654 shares during the period. Cooper Financial Group's holdings in Boston Scientific were worth $900,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of the stock. GAMMA Investing LLC boosted its stake in Boston Scientific by 15.4% during the second quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider's stock worth $3,167,000 after buying an additional 3,932 shares during the period. Bank of New Hampshire lifted its holdings in shares of Boston Scientific by 552.0% in the 2nd quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider's stock worth $2,119,000 after acquiring an additional 16,699 shares during the last quarter. NS Partners Ltd boosted its stake in shares of Boston Scientific by 1.6% during the 1st quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider's stock worth $37,143,000 after purchasing an additional 5,704 shares during the period. MRA Advisory Group bought a new position in Boston Scientific during the 2nd quarter valued at about $273,000. Finally, Neville Rodie & Shaw Inc. grew its holdings in Boston Scientific by 95.9% during the 2nd quarter. Neville Rodie & Shaw Inc. now owns 45,460 shares of the medical equipment provider's stock valued at $4,883,000 after purchasing an additional 22,255 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Boston Scientific Stock Performance

BSX stock opened at $95.78 on Thursday. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $109.50. The business has a 50-day moving average price of $103.30 and a 200 day moving average price of $102.08. The company has a market capitalization of $141.91 billion, a P/E ratio of 57.01, a PEG ratio of 2.35 and a beta of 0.61. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter last year, the firm posted $0.62 EPS. The company's revenue for the quarter was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. BTIG Research boosted their target price on Boston Scientific from $127.00 to $132.00 and gave the company a "buy" rating in a research report on Wednesday. UBS Group boosted their price objective on Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a report on Thursday, July 24th. Leerink Partners increased their target price on Boston Scientific from $127.00 to $128.00 and gave the stock an "outperform" rating in a research note on Wednesday. Jefferies Financial Group reiterated a "hold" rating on shares of Boston Scientific in a research report on Monday, July 21st. Finally, Robert W. Baird upped their price target on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an "outperform" rating in a report on Wednesday. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $120.67.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares of the company's stock, valued at $18,659,923.46. This represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 174,214 shares of company stock worth $17,972,457. 0.50% of the stock is currently owned by corporate insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.